We have used polyclonal anti-synthetic peptide serum to study the role of retinoblastoma gene (RB) inactivation in a variety of human tumor cell lines. Our analysis indicates that inactivation of the RB protein, p105-Rb, is universal in retinoblastoma cells, vindicating the predictions of the Knudson "two-hit" hypothesis. In addition, our analysis has shown that inactivations of the RB gene are nearly as frequent in a more common human tumor, small cell lung carcinoma. One-third of bladder carcinomas surveyed also carry altered or absent p105-Rb. Other human tumors by contrast demonstrate only infrequent inactivation of the RB gene. These results suggest that inactivation of the RB gene is a critical step in the pathogenesis of a subset of human tumors.
The recent isolation of molecular clones of the retinoblastoma gene (RB) has made it possible to evaluate the role of RB gene inactivation in the genesis of a variety of human tumors (1) (2) (3) . These molecular analyses have confirmed and extended earlier karyotypic and genetic studies that had implied that both copies ofthis gene suffer inactivation during the formation of retinoblastomas and several types of sarcoma (4) (5) (6) (7) (8) (9) (10) . Since the inactivation ofRB function appears to trigger tumorigenesis, the RB gene has been termed a "tumor suppressor" gene, whose expression is required to constrain normal cellular proliferation.
Analysis of the protein product encoded by the RB gene, p105-Rb, has shown it to be a nuclear phosphoprotein having an affinity for DNA (11, 12) . This protein may be involved in growth regulation in a wide variety of cell types. Thus, expression of p105-Rb has been detected in all human cells examined except certain types of tumor cells that have suffered RB gene inactivations (ref. 11; J.M.H., unpublished observations). Recent evidence has shown that the RB gene and its encoded protein are also involved in a second, quite distinct, mechanism of tumor formation: oncoproteins specified by three DNA tumor viruses [adenovirus, simian virus 40 (SV40), and human papillomavirus] complex with p105-Rb (13) (14) (15) (16) . This complex formation is apparently central to the ability of these oncoproteins to transform primary cells (14, 17) .
In the initial studies designed to detect inactivation of chromosomal copies of the RB gene, cloned segments of the RB gene were used as probes in Southern blot analysis of tumor DNAs (1) (2) (3) (18) (19) (20) (21) . These studies revealed alterations in the RB gene in as many as 30o of retinoblastomas and heritable osteosarcomas. Unanswered was the genetic status of the remaining 70%o of tumors belonging to these classes.
Their RB genes could have suffered subtle alterations in structure of the sort that escape detection by Southern blotting analysis. Indeed, several recent reports have documented subtle genetic changes in the RB gene that could lead to its functional inactivation (12, 22) . However, it is also possible that the majority of retinoblastomas and sarcomas carry intact RB alleles and that these particular tumors arise because ofalterations in other, as yet uncharacterized, genes. To address this problem, we have employed a more sensitive analysis of RB inactivation by analyzing the RB-encoded p105 protein in 18 independent retinoblastoma tumor cell lines. In addition, we have extended this strategy to an analysis of the frequency of RB gene inactivation in several additional types of human tumors.
MATERIALS AND METHODS
Preparation of Cell Lysates and Immunoprecipitation of the RB Protein from Human Tumor Cells. Tumor cell cultures were incubated for 3-5 hr with [35S~methionine, and cell lysates were prepared as described (13) . Immunoprecipitations were performed with rabbit serum no. 147, 144, or 140 (13) , and precipitates were resolved by electrophoresis for 15 hr on SDS/polyacrylamide gels, processed for fluorography, and exposed for 1-3 days at -70'C. Bladder, colon, and breast carcinoma cultures were acquired from the American Type Culture Collection as were two retinoblastoma cultures (Y79 and WERI-1). The derivation ofall other retinoblastoma cultures and small cell lung carcinoma (SCLC) cultures has been described (1, 23, 24) . Melanoma tumor cells were a kind gift of Nick Dracopoli of the Massachusetts Institute of Technology.
Amplification ofTumor Cell mRNA by Using the Polymerase Chain Reaction (PCR) Technique and DNA Sequence Analysis. RB mRNA was specifically amplified by using oligonucleotide primers from the RB cDNA sequence and the PCR as described (12) . Amplified fragments were cloned into M13 and sequenced on both strands by the dideoxy chain termination technique (25) . Sequences from each culture were confirmed by analysis of several independent phage clones produced from two independent RNA amplification reactions. 
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corroborated by immunoprecipitations with two other polyclonal sera, nos. 140 and 144, produced against two distinct synthetic peptides (13) . In each instance no RB-related proteins were detected (data not shown).
We note that the majority (13/18) of these retinoblastomas were characterized as cell cultures grown for relatively short periods of time (5-10 passages) following explantation of tumors from patients. This suggests that the absence of detectable RB protein is not an artifact of extensive passaging and adaptation to tissue culture. Although the majority of retinoblastoma tumor cell lines did not express detectable levels of wild-type RB messenger RNA, four retinoblastoma tumor cell cultures (RBLA-10, RBLA-18, RBLA-20, and RBLA-22) expressed detectable levels ofintact RB mRNA as judged by Northern blot analysis with an RB cDNA probe (data not shown). We presume that the RB mRNA in these cultures contain mutations that specify aberrant versions of p105-Rb, which do not accumulate to steady-state levels readily detectable by immunoprecipitation.
Although some data has suggested that inactivation of the RB gene is only involved in a small minority of retinoblastomas (20) , we conclude from the present results that RB gene inactivation is universal in retinoblastomas and that earlier analyses of RB gene structure have led to underestimates of the frequency ofinvolvement ofthis gene in the pathogenesis of these tumors. Our data create a puzzle, since many of the mutations capable of inactivating RB gene function should specify defective proteins that are readily detectable in tumor cells (e.g., see below). We are left with the speculation that even marginally defective, aberrant RB proteins are not tolerated in retinoblastomas and are rapidly degraded in these tumor cells.
The RB Gene Is Inactivated in Most SCLC. Encouraged by the utility of p105-Rb analysis, we extended our study to SCLC; an earlier report showed structural abnormalities in the RB gene in 18% of SCLC tumor cell lines and the absence ofRB mRNA in as many as 60% ofthese lines (23) . Here once again analysis of protein proved more sensitive and decisive than nucleic acid analysis (Fig. 1B) . We studied p105-Rb in 9 10 11 12 13 14 15 16 17 18 2 3 4 5 6 7 8 9 10 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 Proc. Natl. Acad Sci. USA 87 (1990) nine SCLC cell lines, all of which were previously characterized as expressing intact RB mRNA (23) . Only one ofthese lines, NCI-H841, expressed levels of intact p105-Rb equivalent to those found in control cell lines (e.g., non-SCLC lung neoplasias; see below). The RB protein was fully absent from five tumor cell lines (NCI-H510, NCI-H711, NCI-H1092, NCI-H1105, and NCI-H1184) and present as an aberrantly migrating species in the remaining three (NCI-H209, NCI-H69C, and NCI-H1436). The RB proteins of cell lines NCI-H69C and NCI-H1436 migrate in SDS/polyacrylamide gels with apparent molecular masses 3-4 kDa less than that of wild-type p105-Rb (Fig. 1B) (29, 30) . Reminiscent of our previous results with the J82 human bladder carcinoma cell line, both of these mutations affect splicing of the RB mRNA precursor, leading to the elimination of an exon and to the truncation of RB mRNA and resulting protein (12) . In one mutant, NCI-H69C, the mRNA encoding exon 21 of the RB gene is fused in-frame directly to exon 23, eliminating 38 amino acids of the exon 22 coding sequence from the RB message and the resulting protein. This is consistent with the observed increased mobility ofthis RB gene product on polyacrylamide gels (Fig. 1B) . PCR amplification and direct sequencing of genomic DNA flanking and including exon 22 in this cell line shows a single point mutation that simultaneously creates a stop codon and a novel splice donor site 30 nucleotides into exon 22 (Fig. 2) . As only mutant exon 22 sequences were detected in the genomic DNA of NCI-H69C, we presume this mutation to be hemi-or homozygous in the genome of this cell line. Since this mutation results in the biogenesis of an RB mRNA that lacks exon 22, we presume that this mutation influences utilization of the normal splice acceptor site immediately upstream of exon 22 or destabilizes full-length RB (Fig. 3) . Loss of this same exon by a similar splicing mutation has previously been documented in the J82 bladder cell line (12) . Sequence analysis of 400 nucleotides of genomic DNA flanking and including exon 21 of NCI-1436 cells shows a single hemi-or homozygous point mutation within intron sequences five nucleotides downstream from the 3' end of exon 21 (Fig. 2) . This mutation falls within a region near the splice donor site known to be well conserved among other such sites (31 . At the bottom, the cell lines from which the cDNAs were prepared are indicated. Wild-type RB cDNA was isolated as described (1) . RB cDNA prepared from J82 bladder carcinoma cells was translated and run in parallel as a control (12) . Molecular mass markers (in kDa) are shown on the left.
presume that this point mutation prevents incorporation of exon 21 sequences into RB mRNA by an as yet unknown mechanism. Taken together, we have identified three splicing mutations, within the RB genes oftumor cells, that lead to the production of truncated and presumably nonfunctional RB proteins. Each is apparently unable to associate with two viral oncoproteins due to the deletion of sequences contained within a 73-amino acid region of p105-Rb. We presume from our results that a binding site for ElA and SV40 large tumor antigen resides within this segment of p105-Rb. Nonetheless we cannot exclude the possibility that deletions within this region affect oncoprotein binding to other domains of this protein.
Whether the location of these three splicing mutations, all clustered in the exon 21-22 region, are coincidental or reflect selection for stable, nonfunctional proteins remains to be determined. Since similar splicing mutations leading to exon loss and in-frame fusion of flanking exons can be predicted to occur throughout the RB gene, the latter hypothesis seems likely. Inactivations of the RB Genes Are Infrequently Associated with Several Other Human Tumors. In contrast with our experience with retinoblastoma and SCLC cultures, we have identified instances of RB gene inactivations only infrequently in several other human tumor cell types. In an earlier report, we described a defective RB allele in a human bladder carcinoma line, J82 (12) . This result suggested the involvement of the RB gene in the genesis of bladder carcinomas, a possibility that we have investigated through examination of the RB protein in 16 independent human bladder tumor cell lines. In 5 of these tumor lines (MGHU-5, 5637, DTB-5, HT1376, and TCCSUP) RB protein was undetectable; the sixth was the previously studied J82 bladder carcinoma line, which carries a splicing mutation leading to the production of a slightly truncated version of the RB protein (Fig. 1C) . The independence of all of these tumor cell lines was confirmed through use of five distinct highly polymorphic restriction fragment length polymorphism probes mapping to chromosome 13 (p68RS2.0, p88PRO.6, and p95HSO.5; ref. 32), to chromosome 2 (pYNH24; ref. 33 ), and to chromosome 17 (pYNZ22; ref. 33) . We conclude that RB inactivation occurs and presumably plays an etiologic role in about one-third of bladder carcinomas or their derived cell lines. Absent from this group is the EJ/T24 bladder carcinoma, which carries a ras oncogene together with apparently normal RB alleles (34) .
To determine whether the absence of the RB protein from the five bladder tumor lines was due to detectable deletions ofthe RB gene, Southern blot analysis was performed with an RB cDNA probe (Fig. 4) . Of the five lines, three exhibit gross deletions of the RB gene (TCCSUP, MGHU-5, and DTB-5). We presume that the other two RB protein-negative cell lines carry subtle mutations, akin to those described above, that abrogate the production of stable RB protein.
These results caused us to examine whether or not RB inactivation is frequently involved in other types of epithelial tumors. Accordingly, we examined 11 cell lines derived from another common epithelial tumor, human colon carcinoma (Fig. 1D) . All 11 colon tumor lines showed normal levels of p105-Rb that in all instances comigrated with RB protein precipitated from control cultures. The independence of these tumor lines was again confirmed using the restriction fragment length polymorphism probes employed in our analysis of bladder cells. We conclude from these results that absent or aberrant RB protein is not frequently associated with the etiology of colon cancers or their derived cell lines.
To extend these results to two other common human tumor types, we examined 12 breast carcinoma cell lines and 10 melanoma cell lines for their expression of p105-Rb ( Fig. 1 E  and F) . The RB alleles in primary breast tumors and breast cell lines have recently been studied by others (35, 36) . All breast cell lines we examined but two, MDA-MB468 and MDA-MB436, contained normal levels of p105-Rb. These two cell lines were also found in previous studies to carry defective RB genes (35, 36) . All 10 melanoma tumor lines we examined produced abundant levels of apparently wild-type p105-Rb. Taking the previous analyses together with our own, we conclude that RB inactivation is relatively infrequent in human mammary carcinoma and melanoma cell lines. In all of these analyses, we assume that the presence of normal amounts of correctly migrating p105-Rb is indicative of intact RB alleles. Thus, we cannot exclude the possibility that some of the ostensibly normal p105-Rb found in the mammary and colon carcinoma lines in fact carry subtle structural alterations that cripple function. (4) (5) (6) (7) (8) (9) (10) . In rare instances, other tumor types have been reported at increased frequency in such hemizygous individuals (37, 38 
